Header Logo

Connection

KENNETH MCCLAIN to Child

Back to Details
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Child.
KENNETH MCCLAIN
Connection Strength
0.693
Child
  1. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929.
    View in: PubMed
    Score: 0.035
  2. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018 Oct - Nov; 35(7-8):427-433.
    View in: PubMed
    Score: 0.034
  3. HLH: watch and wait, or act and cure? Blood. 2018 11 08; 132(19):2005-2006.
    View in: PubMed
    Score: 0.034
  4. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.032
  5. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. J Pediatr. 2017 10; 189:72-78.e3.
    View in: PubMed
    Score: 0.031
  6. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
    View in: PubMed
    Score: 0.029
  7. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011 Jan; 56(1):154-5.
    View in: PubMed
    Score: 0.019
  8. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010 Apr 15; 184(8):4557-67.
    View in: PubMed
    Score: 0.018
  9. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar; 54(3):416-23.
    View in: PubMed
    Score: 0.018
  10. Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race. Pediatr Blood Cancer. 2010 Mar; 54(3):424-8.
    View in: PubMed
    Score: 0.018
  11. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009 May; 52(5):621-5.
    View in: PubMed
    Score: 0.017
  12. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.017
  13. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan; 52(1):97-101.
    View in: PubMed
    Score: 0.017
  14. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008 Jun; 50(6):1227-35.
    View in: PubMed
    Score: 0.016
  15. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan; 48(1):44-9.
    View in: PubMed
    Score: 0.015
  16. Clofarabine for relapsed/refractory LCH and non-LC histiocytosis. Blood Adv. 2026 07 28; 10(14):5087-5096.
    View in: PubMed
    Score: 0.014
  17. Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis. Pediatr Blood Cancer. 2026 Sep; 73(9):e70525.
    View in: PubMed
    Score: 0.014
  18. Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis. Blood Adv. 2026 07 14; 10(13):4776-4785.
    View in: PubMed
    Score: 0.014
  19. Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells. Blood Adv. 2026 Apr 28; 10(8):2711-2726.
    View in: PubMed
    Score: 0.014
  20. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 07 10; 146(2):206-218.
    View in: PubMed
    Score: 0.013
  21. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.012
  22. Langerhans cell histiocytosis patients have HLA Cw7 and DR4 types associated with specific clinical presentations and no increased frequency in polymorphisms of the tumor necrosis factor alpha promoter. Med Pediatr Oncol. 2003 Dec; 41(6):502-7.
    View in: PubMed
    Score: 0.012
  23. Neuroimaging in Pediatric Patients with Juvenile Xanthogranuloma of the CNS. AJNR Am J Neuroradiol. 2022 11; 43(11):1667-1673.
    View in: PubMed
    Score: 0.011
  24. Clinical and molecular features of pediatric cancer patients with Lynch syndrome. Pediatr Blood Cancer. 2022 11; 69(11):e29859.
    View in: PubMed
    Score: 0.011
  25. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621.
    View in: PubMed
    Score: 0.011
  26. IFN-? signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Adv. 2021 09 14; 5(17):3457-3467.
    View in: PubMed
    Score: 0.010
  27. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.010
  28. Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study. Blood Adv. 2020 08 11; 4(15):3754-3766.
    View in: PubMed
    Score: 0.009
  29. BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv. 2019 06 25; 3(12):1848-1853.
    View in: PubMed
    Score: 0.009
  30. A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America. Pediatr Blood Cancer. 2019 08; 66(8):e27798.
    View in: PubMed
    Score: 0.009
  31. Hepatobiliary Dysfunction and Disseminated Intravascular Coagulation Increase Risk of Mortality in Pediatric Hemophagocytic Lymphohistiocytosis. Pediatr Crit Care Med. 2018 10; 19(10):e522-e530.
    View in: PubMed
    Score: 0.008
  32. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
    View in: PubMed
    Score: 0.008
  33. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
    View in: PubMed
    Score: 0.008
  34. Role of staging bone marrow examination in children with Hodgkin disease. Med Pediatr Oncol. 1998 Mar; 30(3):175-7.
    View in: PubMed
    Score: 0.008
  35. PET/MR in the Assessment of Pediatric Histiocytoses: A Comparison to PET/CT. Clin Nucl Med. 2017 Aug; 42(8):582-588.
    View in: PubMed
    Score: 0.008
  36. Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget. 2017 Jul 11; 8(28):46065-46070.
    View in: PubMed
    Score: 0.008
  37. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018 Feb; 36(1):307-315.
    View in: PubMed
    Score: 0.007
  38. Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.007
  39. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.007
  40. Recognition and treatment of concurrent active and neurodegenerative langerhans cell histiocytosis: a case report. J Pediatr Hematol Oncol. 2015 Jan; 37(1):e37-40.
    View in: PubMed
    Score: 0.006
  41. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood. Br J Haematol. 2015 Apr; 169(2):241-8.
    View in: PubMed
    Score: 0.006
  42. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015 Jan 22; 125(4):591-9.
    View in: PubMed
    Score: 0.006
  43. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014 Nov; 165(5):990-6.
    View in: PubMed
    Score: 0.006
  44. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2014; 7(9):6225-30.
    View in: PubMed
    Score: 0.006
  45. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
    View in: PubMed
    Score: 0.006
  46. Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol. 2014 Apr; 31(3):253-7.
    View in: PubMed
    Score: 0.006
  47. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar; 61(3):479-87.
    View in: PubMed
    Score: 0.006
  48. Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol. 1993 Sep; 85(1):57-62.
    View in: PubMed
    Score: 0.006
  49. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20; 121(25):5006-14.
    View in: PubMed
    Score: 0.006
  50. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
    View in: PubMed
    Score: 0.005
  51. Hemophagocytic lymphohistiocytosis associated with precursor B acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Apr; 56(4):658-60.
    View in: PubMed
    Score: 0.005
  52. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion. 2008 Sep; 48(9):1971-80.
    View in: PubMed
    Score: 0.004
  53. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol. 2005 Mar 01; 174(5):3067-71.
    View in: PubMed
    Score: 0.003
  54. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul; 43(1):81-4.
    View in: PubMed
    Score: 0.003
  55. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004 May; 42(5):438-44.
    View in: PubMed
    Score: 0.003
  56. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J. 2003 Jul; 22(7):663-6.
    View in: PubMed
    Score: 0.003
  57. Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA. 2003 May 14; 289(18):2393-9.
    View in: PubMed
    Score: 0.003
  58. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis. 2003 Feb 01; 36(3):306-12.
    View in: PubMed
    Score: 0.003
  59. Human herpesvirus 6 and cytomegalovirus infections in children with human immunodeficiency virus infection and cancer. Pediatr Infect Dis J. 2002 Feb; 21(2):125-32.
    View in: PubMed
    Score: 0.003
  60. Hodgkin's disease associated with central pontine myelinolysis. Med Pediatr Oncol. 1993; 21(4):311-4.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.